LACTOLOGY FOUNDATION

Tridihexethyl (ATC A03AB08) is a synthetic anticholinergic, antimuscarinic antispasmodic historically used as an adjunct in peptic ulcer disease and for acquired nystagmus, with a typical anticholinergic toxicity profile and no specific data on excretion into human breast milk; in breastfeeding it should generally be avoided or reserved for exceptional indications, with preference for safer alternatives within or outside the A03AB class. Its limited modern use, lack of lactation data, and potential for maternal and infant anticholinergic adverse effects argue for high caution and short, closely monitored courses if no safer option is available.medpedia.framar+3

Pharmacological profile

Tridihexethyl is a synthetic anticholinergic (antimuscarinic) and antispasmodic drug, classified in the WHO ATC system as A03AB08 within “synthetic anticholinergics, quaternary ammonium compounds,” indicated mainly as an adjunct in peptic ulcer treatment and for functional gastrointestinal disorders. It exerts antimuscarinic effects by binding muscarinic acetylcholine receptors (M1–M3), inhibiting vagally mediated reflexes, and thereby reducing gastric acid secretion and gastrointestinal smooth muscle spasm.drugs.ncats+2

Tridihexethyl has also been studied as a treatment for acquired nystagmus, where a small randomized trial reported improvement in 4 of 6 patients completing therapy, although anticholinergic adverse effects limited its utility and it has not become a standard therapy. The drug has been withdrawn from the US market (formerly marketed as Pathilon), and contemporary use appears rare or confined to older formulations and specific markets.pubmed.ncbi.nlm.nih+2

Mechanism of action and systemic exposure

As an antimuscarinic agent, tridihexethyl antagonizes acetylcholine at muscarinic receptors in peripheral tissues, leading to reduced gastric secretions, decreased gastrointestinal motility, and relaxation of smooth muscle. It may interact with M1 receptors in autonomic ganglia and possibly in the central nervous system, as well as M2 receptors in the heart and M3 receptors in smooth muscle and exocrine glands, contributing to both therapeutic effects and anticholinergic toxicity.wikidoc+2

Although some sources emphasize quaternary characteristics and limited blood–brain barrier penetration for related agents, tridihexethyl’s receptor-binding profile (including possible central M1 effects) suggests that central nervous system adverse effects (e.g. confusion, cognitive impairment) may still occur, especially at higher doses or in vulnerable patients. Data on oral bioavailability, plasma protein binding, and half-life are limited in the public domain, but the class generally shows moderate systemic exposure and elimination via hepatic metabolism and renal excretion.semanticscholar+2

Indications and clinical use

According to older pharmacological sources and current encyclopedic entries, tridihexethyl is indicated as an adjunct in the treatment of peptic ulcer disease, typically in combination with other antiulcer drugs, to reduce gastric acid secretion and relieve gastrointestinal spasm. The Bulgarian Medpedia entry describes it as an antimuscarinic, anticholinergic and spasmolytic agent used in combination therapy for ulcer disease and nystagmus, consistent with historical labeling.medpedia.framar+2

In neurology, a small randomized crossover trial evaluated tridihexethyl chloride for acquired nystagmus; approximately two-thirds of patients who completed treatment experienced improvement, but anticholinergic side effects were frequent, and more commonly available agents (e.g. baclofen, gabapentin) are now preferred. Modern guidelines for gastrointestinal pharmacotherapy rarely mention tridihexethyl, reflecting its obsolescence and replacement by safer or better-tolerated agents such as proton pump inhibitors, H2 antagonists, and more selective spasmolytics.derbyshiremedicinesmanagement+2

Adverse effects and toxicology

Tridihexethyl shares the class adverse-effect profile of anticholinergic drugs, including dry mouth, blurred vision, mydriasis, constipation, urinary retention, tachycardia, reduced sweating, and potential heat intolerance. Central effects typical of anticholinergics—such as agitation, confusion, hallucinations, and cognitive impairment—may occur particularly at higher doses, in older adults, and in patients with preexisting central nervous system vulnerability.drugs.ncats+3

Overdose produces the classic anticholinergic toxidrome: severe dry mucosa, hyperthermia, tachyarrhythmias, urinary retention, decreased bowel sounds, mydriasis with loss of accommodation, and neuropsychiatric disturbances; management is supportive, including temperature control, cardiac monitoring, benzodiazepines for agitation or seizures, and, in selected cases, cautious use of physostigmine when no contraindications exist. Long-term use of anticholinergics has been linked to cognitive decline and increased dementia risk in observational studies, and contemporary prescribing guidelines frequently recommend minimizing chronic anticholinergic burden, especially in older patients.semanticscholar+1

Contraindications and precautions

Tridihexethyl is contraindicated in patients with hypersensitivity to the drug or its excipients, as noted in the Medpedia monograph. As with other antimuscarinics, strong relative or absolute contraindications include narrow-angle glaucoma, untreated prostatic hypertrophy with significant urinary retention, severe ulcerative colitis, toxic megacolon, and obstructive gastrointestinal or urinary conditions.wikidoc+2

Caution is warranted in patients with cardiovascular disease (e.g. tachyarrhythmias, coronary artery disease, heart failure), autonomic neuropathy, hepatic or renal impairment, and in the elderly, where anticholinergic cognitive effects and falls are more common. Patients with dry eye syndromes or those using contact lenses may experience worsening symptoms due to reduced lacrimation; those in hot environments are at increased risk of heat stroke due to reduced sweating.derbyshiremedicinesmanagement

Drug interactions

Tridihexethyl can potentiate the anticholinergic adverse effects of other antimuscarinic drugs, including tricyclic antidepressants, some antipsychotics, antihistamines, and antiparkinsonian anticholinergics, leading to additive toxicity. Combined use with other agents that reduce gastrointestinal motility (e.g. opioids) can increase the risk of severe constipation, paralytic ileus, or urinary retention, particularly in predisposed patients.semanticscholar+1

Concomitant use with potassium chloride tablets or capsules may increase the risk of gastrointestinal injury because delayed gastric emptying and reduced motility can prolong mucosal exposure to solid potassium formulations; guidelines generally discourage such combinations for anticholinergic drugs as a class. Pharmacodynamic interactions may also occur with prokinetics (reduced efficacy) and with drugs whose absorption depends on gastric motility or pH, though clinically significant consequences for tridihexethyl specifically are not well documented.derbyshiremedicinesmanagement+1

Use in pregnancy

There are no robust controlled studies on tridihexethyl use in human pregnancy, and it is absent from many contemporary pregnancy fact sheets and databases, reflecting its limited modern use. By analogy to other systemic anticholinergics, potential concerns include maternal tachycardia, decreased gut motility, urinary retention, and theoretical fetal effects, though teratogenicity has not been clearly demonstrated.mothertobaby+2

Given the lack of specific human data and the availability of safer, better-studied alternatives for peptic ulcer disease and functional gastrointestinal disorders (e.g. PPIs, H2 blockers, certain locally acting spasmolytics), tridihexethyl should generally be avoided in pregnancy unless no suitable alternative exists and potential benefits clearly outweigh risks. When exposure occurs unintentionally, standard practice is to reassure patients that anticholinergics have not been strongly associated with major malformations, while arranging appropriate obstetric follow-up.semanticscholar+1

Lactation: transfer into milk and infant risk

No direct data on tridihexethyl levels in human breast milk or breastfed infants were identified in open lactation-specific databases, suggesting that this agent has not been systematically studied in breastfeeding. Therefore, its lactation risk assessment relies on pharmacological class effects, known systemic exposure, and extrapolation from other anticholinergics that have been better studied in nursing women.ncbi.nlm.nih+4

Evidence for related anticholinergics (e.g. trihexyphenidyl and other centrally acting agents) indicates that long-term anticholinergic therapy can reduce milk production or interfere with milk let-down, likely through inhibition of prolactin or oxytocin release; animal studies and non-lactating women show reduced prolactin with anticholinergics. Clinical data from one case series report trihexyphenidyl use up to 4 mg daily with haloperidol during multiple pregnancies and lactation periods without apparent adverse developmental outcomes in breastfed infants, although this does not directly involve tridihexethyl and may underestimate subtle effects.drlact+1

Maternal effects on lactation and milk production

Anticholinergic agents can inhibit lactation in animals by suppressing pituitary hormone release (notably growth hormone and oxytocin), and they can lower serum prolactin in non-nursing women. In established lactation, prolactin reductions may not completely abolish milk production, but they can contribute to decreased supply, delayed let-down, or reduced milk ejection, especially when combined with other negative factors (stress, poor latch, inadequate stimulation).drlact+1

For tridihexethyl, these class-based concerns suggest that chronic or high-dose therapy could impair milk production or ejection, particularly early in lactation; short-term, low-dose use is less likely to have a clinically significant effect, although individual susceptibility varies. Breastfeeding women receiving anticholinergics should be counselled to monitor for signs of decreased milk supply (e.g. reduced infant weight gain, fewer wet diapers, less audible swallowing) and to seek professional support if these occur.drlact+1

Expected infant exposure and clinical manifestations

Infant exposure to tridihexethyl via breast milk is unknown but is likely to be low to moderate for typical therapeutic doses, given the class characteristics of systemic anticholinergics and their relatively limited oral bioavailability in infants. Nonetheless, even small exposures could theoretically produce anticholinergic symptoms in susceptible neonates or young infants, including dry mouth, poor sucking, constipation, urinary retention, tachycardia, irritability, or sedation.derbyshiremedicinesmanagement+1

Because tridihexethyl may have limited central penetration compared with tertiary amines, the risk of severe central nervous system depression may be lower than for agents like atropine, but this has not been empirically verified in lactating dyads. Premature infants, those with underlying cardiac or neurologic disease, and neonates in the early postnatal period are likely to be more vulnerable to any anticholinergic exposure, warranting particular caution.pubmed.ncbi.nlm.nih+3

Duration–risk considerations

In the absence of direct milk pharmacokinetic data, duration of maternal therapy becomes a key modifiable factor in risk management for tridihexethyl during lactation. Short-term courses (e.g. a few days) at the lowest effective dose are less likely to meaningfully affect milk production or infant exposure, especially when lactation is well established and the infant is older, though careful observation remains advisable.drlact+1

By contrast, prolonged or chronic therapy could cumulatively reduce milk supply and increase the risk of infant anticholinergic symptoms, especially if additional anticholinergic medications are co-prescribed; in such scenarios, alternative treatments with more favorable lactation safety profiles should be actively sought. When ongoing anticholinergic therapy is essential, regular review of necessity, dose minimization, and close monitoring of both mother and infant should be standard practice.drlact+2

Practical prescribing recommendations in breastfeeding

For breastfeeding women, tridihexethyl should generally be considered a high-caution or “avoid if possible” drug, given its obsolete status, lack of lactation data, and the availability of safer alternatives for gastrointestinal and neurological indications. Where an antispasmodic or anticholinergic is considered necessary, preference should be given to agents with better-characterized lactation safety (e.g. locally acting spasmolytics with minimal systemic absorption) or non-anticholinergic alternatives when clinically appropriate.e-lactation+3

If tridihexethyl use is nevertheless deemed necessary—such as in a rare case where it provides unique benefit for refractory nystagmus—clinicians should use the lowest effective dose, limit duration, avoid co-prescribing additional anticholinergics, and arrange close follow-up for both mother and infant, including monitoring of infant weight gain, hydration, behavior, and signs of anticholinergic toxicity. Informed shared decision-making is essential, with explicit discussion of the paucity of lactation data and the rationale for choosing this medication over better-studied alternatives.pubmed.ncbi.nlm.nih+2

Summary for gastroenterology and lactology practice

From a gastroenterological perspective, tridihexethyl represents an older-generation antispasmodic and antiulcer adjunct that has been largely supplanted by more effective and safer therapies, particularly acid-suppressing drugs and alternative spasmolytics. Its anticholinergic toxicity profile and contraindications mirror those of the broader A03AB class, including typical peripheral and potential central antimuscarinic adverse effects.drugs.ncats+3

From a lactology perspective, the absence of specific breastfeeding data for tridihexethyl, combined with mechanistic concerns about reduced milk production and potential infant anticholinergic exposure, supports a cautious or avoidant stance during breastfeeding whenever clinically feasible. When therapeutic necessity is argued, clinicians should apply general anticholinergic lactation principles: prefer short courses, lowest effective dose, avoid poly-anticholinergic regimens, and monitor closely for maternal and infant adverse effects.e-lactation+3